Publication | Open Access

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

ThrombosisDose-finding Phase 2Cardiovascular DiseasePharmacologyCardiovascular PharmacologyFibrinolysisPharmacotherapyCoagulopathyAtrial FibrillationPublic HealthMedicineAnticoagulantCardiology